The publisher
About Order PT-141.
An independent editorial project that sets the PT-141 (bremelanotide) research record in order — and is careful about what it is, and what it is not.
What this project is
Order PT-141 is an independent editorial project that publishes summaries of the peer-reviewed research literature on PT-141 (bremelanotide). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The approach is the one the name implies: set the record in order. The compound sits in a corner of the internet crowded with sales pitches and sensational claims, and the editorial job here is the opposite — to arrange what the trials actually measured, state the approval scope precisely, foreground the tolerability cost honestly, and mark the gaps where the data stop. Every quantitative clinical claim is cited to a primary source.
What 'order' means here, and what it does not
The 'order' in Order PT-141 refers to putting the literature in order — arranging the evidence into a composed, readable record. It does not refer to a purchase. This site lists no prices, stocks no inventory, and points to no vendor. The domain name is editorial framing, not a storefront.
That distinction governs everything on the site. We report the bremelanotide label dose as a documented finding, never as a regimen for any reader to follow. We summarize the off-label male research as investigational, never as established. And we quarantine community anecdote in a single, clearly-labeled field-reports section that is kept structurally apart from the cited evidence, so that the two are never confused.
How the sourcing works
The clinical content draws on the primary record: the RECONNECT Phase 3 trials and their long-term extension, the mechanistic neuroimaging study, the foundational melanocortin pharmacology, the bremelanotide prescribing information, the Phase 1 metabolic work, and the critical re-analyses that argue the effect is modest. Recent 2024-2025 studies and reviews are included with their evidence tier noted. The full list lives on the study references page.
Where the literature disagrees — most visibly on how meaningful the desire effect is — we present both sides rather than resolving them for the reader. The record is more useful honest than tidy.